Insiders Are Buying These 11 Penny Stocks
In this article, we will take a detailed look at Insiders Are Buying These 11 Penny Stocks. For a quick overview of such stocks, read our article Insiders Are Buying These 5 Penny Stocks. US stock ma...
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
| 3.81 | |
| 4 | |
| - | |
| 4.16 | |
| 3.62 | |
| 3.27-72 | |
| 3 157 K | |
| 798 K | |
| 0 | |
| 0.026 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
In this article, we will take a detailed look at Insiders Are Buying These 11 Penny Stocks. For a quick overview of such stocks, read our article Insiders Are Buying These 5 Penny Stocks. US stock ma...
Developing groundbreaking drugs and devices entails high costs, uncertain regulatory approval, and lucrative revenues. Those factors and more culminate to create a sector filled with dozens of biotech...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also: